Advanced Enzyme Technologies Limited (ADVENZYMES.BO) Stock Competitors & Peer Comparison

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, ASIANPAINT.NS has a market cap of 2.6T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while ASIANPAINT.NS trades at ₹2,748.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas ASIANPAINT.NS's P/E ratio is 60.79. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ASIANPAINT.NS's ROE of +0.22%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ASIANPAINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ASIANPAINT.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, ASIANPAINT.BO has a market cap of 2.6T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while ASIANPAINT.BO trades at ₹2,748.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas ASIANPAINT.BO's P/E ratio is 68.10. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ASIANPAINT.BO's ROE of +0.22%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ASIANPAINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ASIANPAINT.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, PIDILITIND.NS has a market cap of 1.6T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while PIDILITIND.NS trades at ₹1,571.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas PIDILITIND.NS's P/E ratio is 65.59. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PIDILITIND.NS's ROE of +0.24%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to PIDILITIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PIDILITIND.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, PIDILITIND.BO has a market cap of 1.6T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while PIDILITIND.BO trades at ₹1,571.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas PIDILITIND.BO's P/E ratio is 69.84. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PIDILITIND.BO's ROE of +0.24%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to PIDILITIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PIDILITIND.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, SOLARINDS.BO has a market cap of 1.6T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while SOLARINDS.BO trades at ₹16,895.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas SOLARINDS.BO's P/E ratio is 93.34. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SOLARINDS.BO's ROE of +0.33%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to SOLARINDS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SOLARINDS.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, SOLARINDS.NS has a market cap of 1.6T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while SOLARINDS.NS trades at ₹16,899.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas SOLARINDS.NS's P/E ratio is 93.32. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SOLARINDS.NS's ROE of +0.33%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to SOLARINDS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SOLARINDS.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, SRF.BO has a market cap of 807.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while SRF.BO trades at ₹2,742.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas SRF.BO's P/E ratio is 43.94. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SRF.BO's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to SRF.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SRF.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, SRF.NS has a market cap of 806.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while SRF.NS trades at ₹2,744.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas SRF.NS's P/E ratio is 43.89. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SRF.NS's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to SRF.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SRF.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, BERGEPAINT.NS has a market cap of 605.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while BERGEPAINT.NS trades at ₹510.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas BERGEPAINT.NS's P/E ratio is 53.66. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BERGEPAINT.NS's ROE of +0.18%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to BERGEPAINT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BERGEPAINT.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, BERGEPAINT.BO has a market cap of 605.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while BERGEPAINT.BO trades at ₹509.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas BERGEPAINT.BO's P/E ratio is 55.99. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BERGEPAINT.BO's ROE of +0.18%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to BERGEPAINT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BERGEPAINT.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, LINDEINDIA.NS has a market cap of 591.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while LINDEINDIA.NS trades at ₹6,991.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas LINDEINDIA.NS's P/E ratio is 107.90. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to LINDEINDIA.NS's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to LINDEINDIA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check LINDEINDIA.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, LINDEINDIA.BO has a market cap of 591.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while LINDEINDIA.BO trades at ₹6,990.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas LINDEINDIA.BO's P/E ratio is 107.78. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to LINDEINDIA.BO's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to LINDEINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check LINDEINDIA.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, FLUOROCHEM.BO has a market cap of 405.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while FLUOROCHEM.BO trades at ₹3,663.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas FLUOROCHEM.BO's P/E ratio is 70.54. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to FLUOROCHEM.BO's ROE of +0.08%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to FLUOROCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check FLUOROCHEM.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, FLUOROCHEM.NS has a market cap of 404.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while FLUOROCHEM.NS trades at ₹3,671.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas FLUOROCHEM.NS's P/E ratio is 70.50. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to FLUOROCHEM.NS's ROE of +0.08%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to FLUOROCHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check FLUOROCHEM.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, HSCL.NS has a market cap of 337.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while HSCL.NS trades at ₹689.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas HSCL.NS's P/E ratio is 44.47. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to HSCL.NS's ROE of +0.18%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to HSCL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check HSCL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, HSCL.BO has a market cap of 336.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while HSCL.BO trades at ₹689.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas HSCL.BO's P/E ratio is 44.56. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to HSCL.BO's ROE of +0.18%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to HSCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check HSCL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, ACUTAAS.NS has a market cap of 253.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while ACUTAAS.NS trades at ₹2,999.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas ACUTAAS.NS's P/E ratio is 88.71. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ACUTAAS.NS's ROE of +0.24%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ACUTAAS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ACUTAAS.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, ACUTAAS.BO has a market cap of 253.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while ACUTAAS.BO trades at ₹2,999.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas ACUTAAS.BO's P/E ratio is 88.58. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ACUTAAS.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ACUTAAS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ACUTAAS.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, ATUL.NS has a market cap of 193.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while ATUL.NS trades at ₹6,584.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas ATUL.NS's P/E ratio is 28.55. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ATUL.NS's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ATUL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ATUL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, ATUL.BO has a market cap of 193.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while ATUL.BO trades at ₹6,588.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas ATUL.BO's P/E ratio is 32.53. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ATUL.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ATUL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ATUL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, AARTIIND.NS has a market cap of 180.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while AARTIIND.NS trades at ₹496.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas AARTIIND.NS's P/E ratio is 43.17. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AARTIIND.NS's ROE of +0.07%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to AARTIIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AARTIIND.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, AARTIIND.BO has a market cap of 180.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while AARTIIND.BO trades at ₹497.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas AARTIIND.BO's P/E ratio is 47.81. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AARTIIND.BO's ROE of +0.07%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to AARTIIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AARTIIND.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, KANSAINER.BO has a market cap of 175.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while KANSAINER.BO trades at ₹215.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas KANSAINER.BO's P/E ratio is 29.94. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to KANSAINER.BO's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to KANSAINER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check KANSAINER.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, KANSAINER.NS has a market cap of 175B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while KANSAINER.NS trades at ₹215.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas KANSAINER.NS's P/E ratio is 29.77. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to KANSAINER.NS's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to KANSAINER.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check KANSAINER.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, DCMSHRIRAM.BO has a market cap of 163.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while DCMSHRIRAM.BO trades at ₹1,050.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas DCMSHRIRAM.BO's P/E ratio is 19.15. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to DCMSHRIRAM.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to DCMSHRIRAM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check DCMSHRIRAM.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, DCMSHRIRAM.NS has a market cap of 163.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while DCMSHRIRAM.NS trades at ₹1,050.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas DCMSHRIRAM.NS's P/E ratio is 19.17. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to DCMSHRIRAM.NS's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to DCMSHRIRAM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check DCMSHRIRAM.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, AETHER.NS has a market cap of 152.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while AETHER.NS trades at ₹1,177.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas AETHER.NS's P/E ratio is 69.38. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AETHER.NS's ROE of +0.10%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to AETHER.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AETHER.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, AETHER.BO has a market cap of 152.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while AETHER.BO trades at ₹1,177.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas AETHER.BO's P/E ratio is 69.32. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AETHER.BO's ROE of +0.10%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to AETHER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AETHER.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, FINEORG.NS has a market cap of 151B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while FINEORG.NS trades at ₹5,037.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas FINEORG.NS's P/E ratio is 36.19. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to FINEORG.NS's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to FINEORG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check FINEORG.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, FINEORG.BO has a market cap of 150.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while FINEORG.BO trades at ₹5,035.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas FINEORG.BO's P/E ratio is 36.16. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to FINEORG.BO's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to FINEORG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check FINEORG.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, BASF.BO has a market cap of 149.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while BASF.BO trades at ₹3,455.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas BASF.BO's P/E ratio is 39.71. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BASF.BO's ROE of +0.11%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to BASF.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BASF.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, BASF.NS has a market cap of 149.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while BASF.NS trades at ₹3,462.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas BASF.NS's P/E ratio is 35.79. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BASF.NS's ROE of +0.11%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to BASF.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BASF.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, GRWRHITECH.BO has a market cap of 147B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while GRWRHITECH.BO trades at ₹6,383.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas GRWRHITECH.BO's P/E ratio is 43.54. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GRWRHITECH.BO's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to GRWRHITECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GRWRHITECH.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, GRWRHITECH.NS has a market cap of 146.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while GRWRHITECH.NS trades at ₹6,380.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas GRWRHITECH.NS's P/E ratio is 43.49. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GRWRHITECH.NS's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to GRWRHITECH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GRWRHITECH.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, ANURAS.NS has a market cap of 144.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while ANURAS.NS trades at ₹1,261.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas ANURAS.NS's P/E ratio is 82.54. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ANURAS.NS's ROE of +0.05%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ANURAS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ANURAS.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, ANURAS.BO has a market cap of 144.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while ANURAS.BO trades at ₹1,264.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas ANURAS.BO's P/E ratio is 82.51. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ANURAS.BO's ROE of +0.05%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ANURAS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ANURAS.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, VINATIORGA.BO has a market cap of 140.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while VINATIORGA.BO trades at ₹1,336.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas VINATIORGA.BO's P/E ratio is 31.70. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to VINATIORGA.BO's ROE of +0.15%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to VINATIORGA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check VINATIORGA.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, VINATIORGA.NS has a market cap of 140.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while VINATIORGA.NS trades at ₹1,336.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas VINATIORGA.NS's P/E ratio is 31.68. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to VINATIORGA.NS's ROE of +0.15%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to VINATIORGA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check VINATIORGA.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, AKZOINDIA.NS has a market cap of 136B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while AKZOINDIA.NS trades at ₹2,986.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas AKZOINDIA.NS's P/E ratio is 6.95. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AKZOINDIA.NS's ROE of +1.07%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to AKZOINDIA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AKZOINDIA.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, AKZOINDIA.BO has a market cap of 136B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while AKZOINDIA.BO trades at ₹2,985.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas AKZOINDIA.BO's P/E ratio is 6.95. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AKZOINDIA.BO's ROE of +1.07%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to AKZOINDIA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AKZOINDIA.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, PRIVISCL.NS has a market cap of 135.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while PRIVISCL.NS trades at ₹3,453.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas PRIVISCL.NS's P/E ratio is 41.45. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PRIVISCL.NS's ROE of +0.27%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to PRIVISCL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PRIVISCL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, PRIVISCL.BO has a market cap of 135.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while PRIVISCL.BO trades at ₹3,454.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas PRIVISCL.BO's P/E ratio is 41.31. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PRIVISCL.BO's ROE of +0.27%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to PRIVISCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PRIVISCL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, PCBL.BO has a market cap of 119.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while PCBL.BO trades at ₹306.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas PCBL.BO's P/E ratio is 59.10. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PCBL.BO's ROE of +0.05%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to PCBL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PCBL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, PCBL.NS has a market cap of 119.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while PCBL.NS trades at ₹305.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas PCBL.NS's P/E ratio is 58.97. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PCBL.NS's ROE of +0.05%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to PCBL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PCBL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, JUBLINGREA.NS has a market cap of 100.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while JUBLINGREA.NS trades at ₹650.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas JUBLINGREA.NS's P/E ratio is 36.43. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JUBLINGREA.NS's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to JUBLINGREA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JUBLINGREA.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, JUBLINGREA.BO has a market cap of 100.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while JUBLINGREA.BO trades at ₹651.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas JUBLINGREA.BO's P/E ratio is 36.42. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JUBLINGREA.BO's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to JUBLINGREA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JUBLINGREA.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, AMIORG.NS has a market cap of 96.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while AMIORG.NS trades at ₹1,176.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas AMIORG.NS's P/E ratio is 119.06. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AMIORG.NS's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to AMIORG.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AMIORG.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, AMIORG.BO has a market cap of 96.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while AMIORG.BO trades at ₹1,176.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas AMIORG.BO's P/E ratio is 118.95. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AMIORG.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to AMIORG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AMIORG.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, ALKYLAMINE.BO has a market cap of 92.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while ALKYLAMINE.BO trades at ₹1,794.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas ALKYLAMINE.BO's P/E ratio is 51.50. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ALKYLAMINE.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ALKYLAMINE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ALKYLAMINE.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, ALKYLAMINE.NS has a market cap of 92.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while ALKYLAMINE.NS trades at ₹1,788.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas ALKYLAMINE.NS's P/E ratio is 51.60. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ALKYLAMINE.NS's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ALKYLAMINE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ALKYLAMINE.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, CLEAN.NS has a market cap of 84.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while CLEAN.NS trades at ₹783.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas CLEAN.NS's P/E ratio is 36.60. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to CLEAN.NS's ROE of +0.16%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to CLEAN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check CLEAN.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, CLEAN.BO has a market cap of 83.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while CLEAN.BO trades at ₹782.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas CLEAN.BO's P/E ratio is 36.66. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to CLEAN.BO's ROE of +0.16%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to CLEAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check CLEAN.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, SUDARSCHEM.NS has a market cap of 70.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while SUDARSCHEM.NS trades at ₹906.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas SUDARSCHEM.NS's P/E ratio is 318.48. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SUDARSCHEM.NS's ROE of +0.01%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to SUDARSCHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SUDARSCHEM.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, SUDARSCHEM.BO has a market cap of 70.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while SUDARSCHEM.BO trades at ₹906.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas SUDARSCHEM.BO's P/E ratio is 132.83. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SUDARSCHEM.BO's ROE of +0.01%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to SUDARSCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SUDARSCHEM.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, BALAMINES.NS has a market cap of 68.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while BALAMINES.NS trades at ₹2,076.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas BALAMINES.NS's P/E ratio is 40.84. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BALAMINES.NS's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to BALAMINES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BALAMINES.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, BALAMINES.BO has a market cap of 68.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while BALAMINES.BO trades at ₹2,077.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas BALAMINES.BO's P/E ratio is 40.76. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BALAMINES.BO's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to BALAMINES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BALAMINES.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, KINGFA.NS has a market cap of 67.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while KINGFA.NS trades at ₹5,087.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas KINGFA.NS's P/E ratio is 34.80. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to KINGFA.NS's ROE of +0.18%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to KINGFA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check KINGFA.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, KINGFA.BO has a market cap of 67.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while KINGFA.BO trades at ₹5,080.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas KINGFA.BO's P/E ratio is 34.81. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to KINGFA.BO's ROE of +0.18%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to KINGFA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check KINGFA.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, GALAXYSURF.NS has a market cap of 62.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while GALAXYSURF.NS trades at ₹1,796.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas GALAXYSURF.NS's P/E ratio is 23.32. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GALAXYSURF.NS's ROE of +0.11%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to GALAXYSURF.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GALAXYSURF.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, GALAXYSURF.BO has a market cap of 62B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while GALAXYSURF.BO trades at ₹1,796.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas GALAXYSURF.BO's P/E ratio is 23.35. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GALAXYSURF.BO's ROE of +0.11%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to GALAXYSURF.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GALAXYSURF.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, NEOGEN.NS has a market cap of 54.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while NEOGEN.NS trades at ₹2,082.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas NEOGEN.NS's P/E ratio is 188.01. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to NEOGEN.NS's ROE of +0.04%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to NEOGEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check NEOGEN.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, NEOGEN.BO has a market cap of 54.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while NEOGEN.BO trades at ₹2,080.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas NEOGEN.BO's P/E ratio is 190.90. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to NEOGEN.BO's ROE of +0.04%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to NEOGEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check NEOGEN.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, GULFOILLUB.NS has a market cap of 48.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while GULFOILLUB.NS trades at ₹992.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas GULFOILLUB.NS's P/E ratio is 13.39. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GULFOILLUB.NS's ROE of +0.23%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to GULFOILLUB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GULFOILLUB.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, GULFOILLUB.BO has a market cap of 48.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while GULFOILLUB.BO trades at ₹993.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas GULFOILLUB.BO's P/E ratio is 13.37. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GULFOILLUB.BO's ROE of +0.23%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to GULFOILLUB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GULFOILLUB.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, INDIGOPNTS.BO has a market cap of 48.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while INDIGOPNTS.BO trades at ₹1,028.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas INDIGOPNTS.BO's P/E ratio is 33.21. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to INDIGOPNTS.BO's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to INDIGOPNTS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check INDIGOPNTS.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, INDIGOPNTS.NS has a market cap of 47.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while INDIGOPNTS.NS trades at ₹1,028.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas INDIGOPNTS.NS's P/E ratio is 33.12. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to INDIGOPNTS.NS's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to INDIGOPNTS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check INDIGOPNTS.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, RESPONIND.BO has a market cap of 46.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while RESPONIND.BO trades at ₹176.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas RESPONIND.BO's P/E ratio is 31.56. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to RESPONIND.BO's ROE of +0.10%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to RESPONIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check RESPONIND.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, RESPONIND.NS has a market cap of 46.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while RESPONIND.NS trades at ₹176.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas RESPONIND.NS's P/E ratio is 31.55. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to RESPONIND.NS's ROE of +0.10%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to RESPONIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check RESPONIND.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, LXCHEM.BO has a market cap of 43B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while LXCHEM.BO trades at ₹154.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas LXCHEM.BO's P/E ratio is 54.14. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to LXCHEM.BO's ROE of +0.04%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to LXCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check LXCHEM.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, LXCHEM.NS has a market cap of 42.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while LXCHEM.NS trades at ₹153.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas LXCHEM.NS's P/E ratio is 54.16. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to LXCHEM.NS's ROE of +0.04%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to LXCHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check LXCHEM.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, TANFACIND.BO has a market cap of 41.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while TANFACIND.BO trades at ₹2,117.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas TANFACIND.BO's P/E ratio is 58.86. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to TANFACIND.BO's ROE of +0.22%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to TANFACIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check TANFACIND.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, ADVENZYMES.NS has a market cap of 41.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while ADVENZYMES.NS trades at ₹368.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas ADVENZYMES.NS's P/E ratio is 24.41. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ADVENZYMES.NS's ROE of +0.11%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ADVENZYMES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ADVENZYMES.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, VISHNU.BO has a market cap of 40.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while VISHNU.BO trades at ₹601.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas VISHNU.BO's P/E ratio is 28.55. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to VISHNU.BO's ROE of +0.15%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to VISHNU.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check VISHNU.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, VISHNU.NS has a market cap of 40.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while VISHNU.NS trades at ₹601.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas VISHNU.NS's P/E ratio is 28.51. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to VISHNU.NS's ROE of +0.15%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to VISHNU.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check VISHNU.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, SOTL.NS has a market cap of 39.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while SOTL.NS trades at ₹605.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas SOTL.NS's P/E ratio is 21.78. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SOTL.NS's ROE of +0.11%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to SOTL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SOTL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, SOTL.BO has a market cap of 39.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while SOTL.BO trades at ₹606.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas SOTL.BO's P/E ratio is 21.83. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SOTL.BO's ROE of +0.11%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to SOTL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SOTL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, POCL.NS has a market cap of 39.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while POCL.NS trades at ₹1,307.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas POCL.NS's P/E ratio is 29.24. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to POCL.NS's ROE of +0.20%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to POCL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check POCL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, POCL.BO has a market cap of 39.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while POCL.BO trades at ₹1,305.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas POCL.BO's P/E ratio is 29.24. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to POCL.BO's ROE of +0.20%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to POCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check POCL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, PREMEXPLN.NS has a market cap of 36.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while PREMEXPLN.NS trades at ₹737.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas PREMEXPLN.NS's P/E ratio is 80.20. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PREMEXPLN.NS's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to PREMEXPLN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PREMEXPLN.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, PREMEXPLN.BO has a market cap of 36.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while PREMEXPLN.BO trades at ₹738.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas PREMEXPLN.BO's P/E ratio is 80.11. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PREMEXPLN.BO's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to PREMEXPLN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PREMEXPLN.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, GRAUWEIL.NS has a market cap of 35.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while GRAUWEIL.NS trades at ₹76.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas GRAUWEIL.NS's P/E ratio is 21.30. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GRAUWEIL.NS's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to GRAUWEIL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GRAUWEIL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, GRAUWEIL.BO has a market cap of 35B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while GRAUWEIL.BO trades at ₹76.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas GRAUWEIL.BO's P/E ratio is 21.31. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GRAUWEIL.BO's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to GRAUWEIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GRAUWEIL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, YASHO.NS has a market cap of 33.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while YASHO.NS trades at ₹2,723.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas YASHO.NS's P/E ratio is 133.00. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to YASHO.NS's ROE of +0.06%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to YASHO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check YASHO.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, YASHO.BO has a market cap of 33.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while YASHO.BO trades at ₹2,729.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas YASHO.BO's P/E ratio is 132.03. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to YASHO.BO's ROE of +0.06%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to YASHO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check YASHO.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, JINDALPOLY.NS has a market cap of 32.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while JINDALPOLY.NS trades at ₹719.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas JINDALPOLY.NS's P/E ratio is -15.25. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JINDALPOLY.NS's ROE of -0.06%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to JINDALPOLY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JINDALPOLY.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, JINDALPOLY.BO has a market cap of 32.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while JINDALPOLY.BO trades at ₹716.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas JINDALPOLY.BO's P/E ratio is -24.96. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JINDALPOLY.BO's ROE of -0.06%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to JINDALPOLY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JINDALPOLY.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, POLYPLEX.BO has a market cap of 28.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while POLYPLEX.BO trades at ₹928.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas POLYPLEX.BO's P/E ratio is 63.62. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to POLYPLEX.BO's ROE of +0.01%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to POLYPLEX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check POLYPLEX.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, POLYPLEX.NS has a market cap of 28.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while POLYPLEX.NS trades at ₹929.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas POLYPLEX.NS's P/E ratio is 63.98. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to POLYPLEX.NS's ROE of +0.01%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to POLYPLEX.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check POLYPLEX.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, ROSSARI.BO has a market cap of 28.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while ROSSARI.BO trades at ₹512.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas ROSSARI.BO's P/E ratio is 19.00. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ROSSARI.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ROSSARI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ROSSARI.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, XPROINDIA.BO has a market cap of 28.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while XPROINDIA.BO trades at ₹1,396.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas XPROINDIA.BO's P/E ratio is 142.99. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to XPROINDIA.BO's ROE of +0.03%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to XPROINDIA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check XPROINDIA.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, XPROINDIA.NS has a market cap of 28.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while XPROINDIA.NS trades at ₹1,393.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas XPROINDIA.NS's P/E ratio is 143.20. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to XPROINDIA.NS's ROE of +0.03%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to XPROINDIA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check XPROINDIA.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, ROSSARI.NS has a market cap of 28.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while ROSSARI.NS trades at ₹513.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas ROSSARI.NS's P/E ratio is 19.01. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ROSSARI.NS's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ROSSARI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ROSSARI.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, JUBLCPL.NS has a market cap of 28.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while JUBLCPL.NS trades at ₹1,874.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas JUBLCPL.NS's P/E ratio is 22.44. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JUBLCPL.NS's ROE of +0.32%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to JUBLCPL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JUBLCPL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, JUBLCPL.BO has a market cap of 28.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while JUBLCPL.BO trades at ₹1,874.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas JUBLCPL.BO's P/E ratio is 22.40. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JUBLCPL.BO's ROE of +0.13%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to JUBLCPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JUBLCPL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, TATVA.BO has a market cap of 27.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while TATVA.BO trades at ₹1,185.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas TATVA.BO's P/E ratio is 65.76. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to TATVA.BO's ROE of +0.06%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to TATVA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check TATVA.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, TATVA.NS has a market cap of 27.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while TATVA.NS trades at ₹1,185.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas TATVA.NS's P/E ratio is 65.51. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to TATVA.NS's ROE of +0.06%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to TATVA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check TATVA.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, NOCIL.NS has a market cap of 27.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while NOCIL.NS trades at ₹161.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas NOCIL.NS's P/E ratio is 49.11. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to NOCIL.NS's ROE of +0.03%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to NOCIL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check NOCIL.NS's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, NOCIL.BO has a market cap of 27.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while NOCIL.BO trades at ₹161.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas NOCIL.BO's P/E ratio is 43.40. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to NOCIL.BO's ROE of +0.03%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to NOCIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check NOCIL.BO's competition here

ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADVENZYMES.BO stands at 40.9B. In comparison, APCOTEXIND.NS has a market cap of 26.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹368.15, while APCOTEXIND.NS trades at ₹521.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADVENZYMES.BO currently has a P/E ratio of 24.35, whereas APCOTEXIND.NS's P/E ratio is 26.46. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to APCOTEXIND.NS's ROE of +0.18%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to APCOTEXIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check APCOTEXIND.NS's competition here